Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Neaton

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Trials (London, England)|December 20, 2012
Panel discussion 2Gordon Lan, Stacy Lindborg, James Neaton
AIDS (London, England)|November 14, 2008
The role of HIV in serious diseases other than AIDSAndrew N Phillips, James Neaton, Jens D Lundgren
Biometrics|April 29, 2021
Nonparametric estimation in an illness-death model with component-wise censoringAnne Eaton, Yifei Sun, James Neaton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 19, 2009
Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratioJens D Lundgren, Andrew N Phillips, James Neaton
The New England Journal of Medicine|April 2, 2003
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionBertram Pitt, Willem Remme, Faiez Zannad, et al.
Clinical Trials (London, England)|March 19, 2019
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials programJay S Shavadia, Abhinav Sharma, Xiangqiong Gu, et al.
The Journal of Infectious Diseases|February 25, 2016
Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM StudyLori E Dodd, Michael A Proschan, Jacqueline Neuhaus, et al.
Ebiomedicine|August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic AnalysisNathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
AIDS (London, England)|November 30, 2020
Losartan to reduce inflammation and fibrosis endpoints in HIV diseaseJason V Baker, Julian Wolfson, Gary Collins, et al.
AIDS Research and Human Retroviruses|December 19, 2013
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41Nathan W Cummins, Jacqueline Neuhaus, Amy M Sainski, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Trials (London, England)|December 20, 2012
Panel discussion 2Gordon Lan, Stacy Lindborg, James Neaton
AIDS (London, England)|November 14, 2008
The role of HIV in serious diseases other than AIDSAndrew N Phillips, James Neaton, Jens D Lundgren
Biometrics|April 29, 2021
Nonparametric estimation in an illness-death model with component-wise censoringAnne Eaton, Yifei Sun, James Neaton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 19, 2009
Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratioJens D Lundgren, Andrew N Phillips, James Neaton
The New England Journal of Medicine|April 2, 2003
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionBertram Pitt, Willem Remme, Faiez Zannad, et al.
Clinical Trials (London, England)|March 19, 2019
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials programJay S Shavadia, Abhinav Sharma, Xiangqiong Gu, et al.
The Journal of Infectious Diseases|February 25, 2016
Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM StudyLori E Dodd, Michael A Proschan, Jacqueline Neuhaus, et al.
Ebiomedicine|August 20, 2015
Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic AnalysisNathan W Cummins, Jacqueline Neuhaus, Haitao Chu, et al.
AIDS (London, England)|November 30, 2020
Losartan to reduce inflammation and fibrosis endpoints in HIV diseaseJason V Baker, Julian Wolfson, Gary Collins, et al.
AIDS Research and Human Retroviruses|December 19, 2013
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41Nathan W Cummins, Jacqueline Neuhaus, Amy M Sainski, et al.
Pageof 2